Gynoflor

Gynoflor is a prescription vaginal cream that combines estriol (0.1 mg per gram) and Lactobacillus acidophilus (10⁷ CFU per gram). The estriol component acts as a weak estrogen, while the probiotic helps maintain normal vaginal flora. Formulated for local use, Gynoflor is intended to address estrogen‑related changes in the vaginal tissue and support microbial balance in post‑menopausal women. It is marketed in the European Union and classified under gynecological hormone therapy.

Gynoflor is indicated for several menopause‑related vaginal conditions where estrogen deficiency leads to tissue changes. - Vulvovaginal atrophy associated with menopause. - Vaginal dryness that interferes with comfort. - Dyspareunia (painful intercourse) linked to thinning of the vaginal epithelium. - Itching or irritation caused by reduced estrogen and altered flora. - Support of normal vaginal microbiota after antibiotic or hormonal disturbances. - Adjunct therapy for women using systemic hormone replacement who require localized symptom relief.

The safety profile of Gynoflor reflects the local action of estriol and the probiotic component.

Common: - Mild vaginal irritation or burning at the application site. - Transient spotting or light bleeding. - Increased vaginal discharge that is clear or whitish. - Local itching that resolves with continued use. - Temporary feeling of warmth in the pelvic area.

Serious: - Allergic reaction such as rash, swelling, or hives. - Severe vaginal bleeding or ulceration. - Signs of estrogen‑dependent tumor progression (e.g., abnormal uterine bleeding). - Persistent pelvic pain or infection. - Rare thromboembolic events reported with systemic estrogen exposure. - Unexplained weight gain or fluid retention.

When prescribing Gynoflor, clinicians consider several precautionary factors to ensure safe and appropriate use. - Not recommended for women with known hypersensitivity to estriol, lactobacilli, or any cream excipients. - Use with caution in patients with a history of estrogen‑dependent cancers (breast, endometrial, ovarian). - Avoid in active vaginal infections until they are adequately treated. - Assess for unexplained vaginal bleeding before initiating therapy. - Monitor patients with thromboembolic risk or cardiovascular disease. - Limit duration of use to the shortest period needed for symptom control.

Gynoflor’s local estrogen component can interact with systemic medications that affect hormone pathways or clotting.

Avoid: - Concurrent use of systemic estrogen therapy or high‑dose hormonal contraceptives without medical supervision. - Antifungal or antibacterial vaginal products that may alter probiotic viability.

Use with caution: - Oral anticoagulants, because estrogen can increase clotting risk. - Hormone‑sensitive cancer treatments, requiring oncologist oversight. - Certain selective estrogen receptor modulators (SERMs) that may have opposing effects. - Systemic corticosteroids, which can affect immune response in the vagina. - Aromatase inhibitors, as they may reduce overall estrogen levels and affect therapeutic response.